JohnELevineMDM.S.

Pediatric Hematology & Oncology • New York, NY

Professor of Internal Medicine and Pediatrics, Louis Aledort Clinical Research Professor in Hematology, Director of BMT Clinical Research

Join to view full profile

Dr. Levine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Levine's full profile

Already have an account?

Office
10 E 102nd St
New York, NY 10029
Phone+1 212-241-6756

Summary

John Levine, MD, based in New York, NY, is a specialist in Pediatric Hematology & Oncology. He completed his residency in Pediatrics at Children's Hospital Los Angeles and further training at Memorial Sloan Kettering Cancer Center after graduating from Eastern Virginia Medical School in 1989. Dr. Levine currently serves as a Professor of Internal Medicine and Pediatrics and Director of BMT Clinical Research at Icahn School of Medicine at Mount Sinai since 2015 where he also serves as co-Director of the Mount Sinai Acute GVHD International Consortium (MAGIC). Previously, he was a Professor of Pediatrics and Internal Medicine at the University of Michigan from 1995 to 2015. His expertise includes bone marrow failure syndromes, hematopoietic stem cell transplantation, graft-versus-host disease, and conducting clinical and translational research. Dr. Levine has published numerous highly cited articles in scientific journals and has served as the Chair of the Cellular Therapy Committee for Children's Oncology Group (COG) and the Chair of the Steering Committee of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Education & Training

Memorial Sloan Kettering Cancer Center1992 - 1995
Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1992
Eastern Virginia Medical SchoolClass of 1989

Certifications & Licensure

NY State Medical License 1992 - 2026
FL State Medical License 2020 - 2023
PA State Medical License 2016 - 2018
MI State Medical License 1995 - 2017
CA State Medical License 1990 - 1995
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants Start of enrollment: 2002 Sep 01
Completed
Phase 1, Phase 2
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2003 Oct 01
Completed
Phase 2
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) Start of enrollment: 2004 Aug 01
Completed
Phase 2
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Start of enrollment: 1997 Jan 01
Completed
Phase 2
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant Start of enrollment: 2003 Apr 01
Completed
Phase 2
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Start of enrollment: 2000 Mar 01
Terminated
Phase 2
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Start of enrollment: 2000 Mar 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant Start of enrollment: 2009 Mar 01
Completed
Phase 2
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) Start of enrollment: 2008 Aug 01
Completed
Phase 2
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
COMPLETED
PHASE3
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2014 Aug 14
Completed
Phase 2
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Start of enrollment: 2017 Mar 16
COMPLETED
PHASE2
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Start of enrollment: 2018 Aug 17
Completed
Phase 2
Itacitinib for Low Risk GVHD Start of enrollment: 2019 Mar 25
Completed
Phase 2
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) Start of enrollment: 2019 Nov 21
Terminated
Phase 3
Pediatric GVHD Low Risk Steroid Taper Trial Start of enrollment: 2022 Oct 20
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
TERMINATED
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Mark C Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K Waller
Blood Advances. 2025-03-11
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier
Bone Marrow Transplantation. 2025-02-27
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
Daniela Guisado, Sayali Talware, Xiaoli Wang, Andrew Davis, Elbek Fozilov
Gut. 2025-02-17

Journal Articles

Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia
John E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature

Abstracts/Posters

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Everything You Need to Know About Graft-Versus-Host DiseaseJanuary 13th, 2023
Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow TransplantDecember 13th, 2022
An Experimental Cancer Treatment Leaves Two Patients 'Cured' After 10 YearsFebruary 18th, 2022
Join now to see all

Grant Support

Phase II Study Of A Novel GVHD Prevention Strategy: Etanercept And PhotopheresisNational Heart, Lung, And Blood Institute2011–2012
Cellular Immunotherapy For Hematologic MalignancyNational Cancer Institute2001–2006
Treatment Of Graft-Versus-Host Disease Using EnbrelFood And Drug Administration2005